* Byetta LAR tops other diabetes drugs in head-to-head * Byetta better at blood glucose control, weight loss * Amylin shares up 17 percent By Bill Berkrot NEW YORK, March 31 (Reuters) - The ...

BOSTON (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced ...

Minor Label Changes and Approval of Once Weekly Version of Drug Are Anticipated The increasing incidence of obesity has ushered in a ripe market for type 2 diabetes drugs. The commercial landscape is ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...

Earlier this month, Amylin (AMLN) and Eli Lilly (LLY) announced that the U.S. Food and Drug Administration (FDA) has implemented label changes for Byetta (exenatide) which is indicated for the ...

Amneal announced the advancement of two key strategic initiatives. Amneal has received approval from the Food and Drug Administration for exenatide, which is the company’s first generic injectable ...

Many analysts are recommending that investors hold off on buying stock in Novo Nordisk because rival Eli Lilly and Co. might encounter a smash hit with a version of its Byetta diabetes treatment that ...

WASHINGTON (AP) - Federal regulators are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after deaths continue to be reported ...